Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy
暂无分享,去创建一个
M. Genovese | J. Tumlin | M. Bubb | P. Rao | W. Chatham | V. Derebail | U. Patel | Y. Chaichian | Matthew C Baker | Sam Lim | O. Gurtovaya | Hooman Hajian | Matthew C. Baker
[1] E. Frangou,et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis , 2020, Annals of the Rheumatic Diseases.
[2] J. Chandrasekhar,et al. Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases. , 2020, ACS medicinal chemistry letters.
[3] K. Kalunian,et al. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. , 2019, JAMA.
[4] R. Landewé,et al. LB0003 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS NAïVE TO METHOTREXATE THERAPY: FINCH3 PRIMARY OUTCOME RESULTS , 2019, Oral Presentations.
[5] R. Landewé,et al. LB0001 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS , 2019, Oral Presentations.
[6] M. Kretzler,et al. OP-NDTJ180031 1942..2019 , 2018 .
[7] Massimo Gadina,et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.
[8] G. Gilkeson,et al. A Critical Role of the Transcription Factor Fli‐1 in Murine Lupus Development by Regulation of Interleukin‐6 Expression , 2014, Arthritis & rheumatology.
[9] L. Ma,et al. Increased Interleukin 21 and Follicular Helper T-like Cells and Reduced Interleukin 10+ B cells in Patients with New-onset Systemic Lupus Erythematosus , 2014, The Journal of Rheumatology.
[10] K. Coggeshall,et al. Interleukin‐6 Deficiency Corrects Nephritis, Lymphocyte Abnormalities, and Secondary Sjögren's Syndrome Features in Lupus‐Prone Sle1.Yaa Mice , 2014, Arthritis & rheumatology.
[11] S. Xiong,et al. Interleukin-6 promotes systemic lupus erythematosus progression with Treg suppression approach in a murine systemic lupus erythematosus model , 2014, Clinical Rheumatology.
[12] V. Shah,et al. Comparison of spot urine protein creatinine ratio with 24 hour urine protein for estimation of proteinuria. , 2014, The Journal of the Association of Physicians of India.
[13] L. Nelles,et al. Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases , 2013, The Journal of Immunology.
[14] D. Webb,et al. What is the best method of proteinuria measurement in clinical trials of endothelin receptor antagonists? , 2012, Life sciences.
[15] S. Chadban,et al. Day-to-day variability in spot urine protein-creatinine ratio measurements. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] Jinoos Yazdany,et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis , 2012, Arthritis care & research.
[17] N. Chen,et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome , 2012, Nephrology.
[18] Victor L. J. Tybulewicz,et al. The SYK tyrosine kinase: a crucial player in diverse biological functions , 2010, Nature Reviews Immunology.
[19] J. Fridman,et al. Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 , 2010, The Journal of Immunology.
[20] W. Ng,et al. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine , 2009, Lupus.
[21] H. Nagaraja,et al. Random Spot Urine Protein/Creatinine Ratio Is Unreliable for Estimating 24-Hour Proteinuria in Individual Systemic Lupus Erythematosus Nephritis Patients , 2009, Nephron Clinical Practice.
[22] G. Illei,et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. , 2009, Journal of the American Society of Nephrology : JASN.
[23] W. Leonard,et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice , 2009, Proceedings of the National Academy of Sciences.
[24] J. Reveille,et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. , 2008, Rheumatology.
[25] M. Petri,et al. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases , 2008, Lupus.
[26] H. Nagaraja,et al. Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. , 2007, Kidney international.
[27] P. Lipsky,et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus , 2007, Annals of the rheumatic diseases.
[28] D. Payan,et al. R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.
[29] A. Mócsai,et al. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs , 2006, Nature Immunology.
[30] D. Furst,et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.
[31] G. Hughes,et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. , 2005, Rheumatology.
[32] C. Lau,et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[33] D. Albert,et al. What do we know about lupus membranous nephropathy? An analytic review. , 2002, Arthritis and rheumatism.
[34] D. Wallace,et al. Cyclosporine for lupus membranous nephritis:experience with ten patients and review of the literature , 2000, Lupus.
[35] T. Chan,et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression , 1999, Lupus.
[36] S. Quaglini,et al. Treatment of membranous lupus nephritis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[37] M. Schwartz,et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. , 1996, Journal of the American Society of Nephrology : JASN.
[38] J. Renauld,et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity , 1995, Lupus.
[39] J. Cameron,et al. Lupus Nephritis , 1959, Clinics in rheumatic diseases.
[40] B. Hutton. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases , 2009 .
[41] L. Pasquier,et al. Orphanet Journal of Rare Diseases BioMed Central Review , 2006 .
[42] J. Killen. Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis. , 2006, The New England journal of medicine.